p16(MTS-1/CDKN2/INK4a) in cancer progression

被引:396
|
作者
Rocco, JW
Sidransky, D
机构
[1] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA
[3] Johns Hopkins Univ Hosp, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21202 USA
关键词
D O I
10.1006/excr.2000.5149
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Since its discovery as an inhibitor of cyclin-dependent kinases 4 and 6, the tumor suppressor pie has continued to gain widespread importance in cancer. The high frequency of deletions of p16 in tumor cell lines first suggested an important role for p16 in carcinogenesis. This initial genetic evidence was subsequently strengthened by numerous studies documenting p16 inactivation in kindreds with familial melanoma. Moreover, a high frequency of p16 gene alterations was found in primary tumors, while recent studies have identified p16 promoter methylation as a major mechanism of tumor-suppressor-gene silencing. Additional insight into pie's role in cancer has come from the genetic analysis of precancerous lesions and various tissue culture models. It is now believed that loss of pie is an early and often critical event in tumor progression. Consequently, pie is a major tumor-suppressor gene whose frequent loss occurs early in many human cancers. (C) 2001 Academic Press.
引用
收藏
页码:42 / 55
页数:14
相关论文
共 50 条
  • [21] p16INK4A/MTS1/CDKN2 -: the melanoma gene?
    Bogenrieder, T
    Landthaler, M
    Stolz, W
    HAUTARZT, 1998, 49 (02): : 91 - 100
  • [22] Incidence and clinical significance of CDKN2/MTS1/p16(ink4A) and MTS2/p15(ink4B) gene deletions in childhood acute lymphoblastic leukemia
    Zhou, MX
    Gu, LB
    Yeager, AM
    Findley, HW
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1997, 14 (02) : 141 - 150
  • [23] Homozygous deletion of the p16/MTS-1/CDKN2 gene in malignant gliomas is infrequent among Japanese patients
    Mochizuki, S
    Iwadate, Y
    Namba, H
    Yoshida, Y
    Yamaura, A
    Sakiyama, S
    Tagawa, M
    INTERNATIONAL JOURNAL OF ONCOLOGY, 1999, 15 (05) : 983 - 989
  • [24] Sporadic CDKN2 (MTS1/p16(ink4)) gene alterations in human ovarian tumours
    Schuyer, M
    vanStaveren, IL
    Klijn, JGM
    vanderBurg, MEL
    Stoter, G
    HenzenLogmans, SC
    Foekens, JA
    Berns, EMJJ
    BRITISH JOURNAL OF CANCER, 1996, 74 (07) : 1069 - 1073
  • [25] MUTATIONAL ANALYSIS OF CDKN2 (MTS1/P16(INK4)) IN HUMAN BREAST-CARCINOMA
    XU, L
    SGROI, D
    STERNER, CJ
    BEAUCHAMP, RL
    PINNEY, DM
    KEEL, S
    UEKI, K
    RUTTER, JL
    BUCKLER, AJ
    LOUIS, DN
    GUSELLA, JF
    RAMESH, V
    CANCER RESEARCH, 1994, 54 (20) : 5262 - 5264
  • [26] CDKN2A (p16(INK4A)) somatic and germline mutations
    SmithSorensen, B
    Hovig, E
    HUMAN MUTATION, 1996, 7 (04) : 294 - 303
  • [27] Growth arrest and suppression of tumorigenicity of bladder-carcinoma cell lines induced by the P16/CDKN2 (p16(INK4A), MTS1) gene and other loci on human chromosome 9
    Wu, Q
    Possati, L
    Montesi, M
    Gualandi, F
    Rimessi, P
    Morelli, C
    Trabanelli, C
    BarbantiBrodano, G
    INTERNATIONAL JOURNAL OF CANCER, 1996, 65 (06) : 840 - 846
  • [28] Inhibition of pRb phosphorylation and cell-cycle progression by a 20-residue peptide derived from p16(CDKN2/INK4A)
    Fahraeus, R
    Paramio, JM
    Ball, KL
    Lain, S
    Lane, DP
    CURRENT BIOLOGY, 1996, 6 (01) : 84 - 91
  • [29] MUTATIONS IN THE P16(INK4)/MTS1/CDKN2, P15(INK4B)/MTS2, AND P18 GENES IN PRIMARY AND METASTATIC LUNG-CANCER
    OKAMOTO, A
    HUSSAIN, SP
    HAGIWARA, K
    SPILLARE, EA
    RUSIN, MR
    DEMETRICK, DJ
    SERRANO, M
    HANNON, GJ
    SHISEKI, M
    ZARIWALA, M
    XIONG, Y
    BEACH, DH
    YOKOTA, J
    HARRIS, CC
    CANCER RESEARCH, 1995, 55 (07) : 1448 - 1451